|Bid||224.92 x 21500|
|Ask||224.96 x 1000|
|Day's Range||224.79 - 225.00|
|52 Week Range||42.65 - 225.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The latest big-ticket acquisition in the healthcare industry has closed. On Tuesday, Bristol Myers Squibb (NYSE: BMY) announced that its buyout of heart medication specialist MyoKardia has been finalized; the latter company is now a fully owned subsidiary, with its stock being delisted from the Nasdaq. Bristol Myers Squibb paid $13.1 billion in cash for its new asset.
Moody's Investors Service ("Moody's") assigned an A2 rating to the new senior unsecured notes of Bristol-Myers Squibb Company ("Bristol"). There are no changes to Bristol's existing ratings including the A2 senior unsecured long-term rating and the Prime-1 commercial paper rating. Bristol's A2 rating reflects its large scale and solid positions in immuno-oncology, hematology and immunology.
Qorvo, Nikola, BMY, MyoKardia and Geron as Zacks Bull and Bear of the Day